Merck still hiring in China despite jobs cull
This article was originally published in Scrip
Merck & Co is to cut up to 13,000 more jobs, on top of the 17% reduction to its workforce that it announced last year. However, it is still hiring in emerging markets as it works to increase the proportion of its pharmaceutical sales from faster-growing economies.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.